Evidence map›Paper›PMID 36044927›Full record

ArticleSeminars in liver disease2022

From a Single Cell to a Whole Human Liver: Disease Modeling and Transplantation.

Takashi Motomura, Lanuza A P Faccioli, Ricardo Diaz-Aragon, Zehra N Kocas-Kilicarslan, Nils Haep, Rodrigo M Florentino, Sriram Amirneni, Zeliha Cetin, Bhaavna S Peri, Kazutoyo Morita and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Seminars in liver disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Takashi Motomura *Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Lanuza A P Faccioli *Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Ricardo Diaz-AragonDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Zehra N Kocas-KilicarslanDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Nils HaepDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Rodrigo M FlorentinoDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Sriram AmirneniDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Zeliha CetinDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Bhaavna S PeriDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Kazutoyo MoritaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Alina OstrowskaDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Kazuki TakeishiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Alejandro Soto-Gutierrez *Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Edgar N Tafaleng *Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
University of Pittsburgh · USKyushu University · JPMcGowan Institute for Regenerative Medicine · US

Funding

Treating AT Deficiency with Drugs that Modulate the Proteostasis NetworkP01DK096990 · NIDDK · WASHINGTON UNIVERSITY · PI PERLMUTTER, DAVID H · 2012 to 2023
$18.3M
Pittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shuchang Silvia Liu · 2019 to 2026
$10.9M
Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanomaU01TR002383 · NCATS · VANDERBILT UNIVERSITY · PI MURPHY, WILLIAM L., TAYLOR, D. LANSING · 2018 to 2022
$7.6M
Human Microphysiology Systems Disease Model of Type 2 Diabetes Starting with Liver and pancreatic IsletsUH3DK119973 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TAYLOR, D. LANSING · 2020 to 2022
$6.7M
Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and TherapyR01DK099257 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NAGRATH, DEEPAK, SOTO-GUTIERREZ, ALEJANDRO · 2014 to 2024
$3.4M
Human Microphysiology Systems Disease Model of Type 2 Diabetes Starting with Liver and pancreatic IsletsUG3DK119973 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TAYLOR, D. LANSING · 2018 to 2019
$2.3M
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver diseaseUH3TR003289 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BEHARI, JAIDEEP, SOTO-GUTIERREZ, ALEJANDRO · 2022 to 2024
$2.3M
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver diseaseUG3TR003289 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BEHARI, JAIDEEP, SOTO-GUTIERREZ, ALEJANDRO · 2020 to 2021
$1.5M
NCATS NIH HHS U01 TR002383NCATS NIH HHS UG3 TR003289NCATS NIH HHS UH3 TR003289NIDDK NIH HHS P01 DK096990NIDDK NIH HHS P30 DK120531NIDDK NIH HHS R01 DK099257NIDDK NIH HHS UG3 DK119973NIDDK NIH HHS UH3 DK119973
6 · The paper itself

Abstract

Although the underlying cause may vary across countries and demographic groups, liver disease is a major cause of morbidity and mortality globally. Orthotopic liver transplantation is the only definitive treatment for liver failure but is limited by the lack of donor livers. The development of drugs that prevent the progression of liver disease and the generation of alternative liver constructs for transplantation could help alleviate the burden of liver disease. Bioengineered livers containing human induced pluripotent stem cell (iPSC)-derived liver cells are being utilized to study liver disease and to identify and test potential therapeutics. Moreover, bioengineered livers containing pig hepatocytes and endothelial cells have been shown to function and survive after transplantation into pig models of liver failure, providing preclinical evidence toward future clinical applications. Finally, bioengineered livers containing human iPSC-derived liver cells have been shown to function and survive after transplantation in rodents but require considerable optimization and testing prior to clinical use. In conclusion, bioengineered livers have emerged as a suitable tool for modeling liver diseases and as a promising alternative graft for clinical transplantation. The integration of novel technologies and techniques for the assembly and analysis of bioengineered livers will undoubtedly expand future applications in basic research and clinical transplantation.

Indexed as

Induced Pluripotent Stem CellsLiver DiseasesLiver FailureAnimalsEndothelial CellsHepatocytesHumansLiverSwine

Identifiers

PMID36044927
PMCPMC9718640
OpenAlexW4294125980

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.